An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

NEW HAVEN, Conn. (WTNH) — A new Yale-led study published Thursday identified a new target for treating the most common form of cancer in children and young adults, B-cell acute lymphoblastic leukemia ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

Acute lymphoblastic leukemia (ALL) is known as a pediatric leukemia, with approximately half of cases occurring in children. ALL is the most common childhood malignancy, representing 75% to 80% of ...

Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B ...

Oncaspar (pegaspargase) is a long-acting prescription injection medicine used for people with a type of blood cancer known as acute lymphoblastic leukemia (ALL). It is also approved specifically for ...